216 related articles for article (PubMed ID: 18571968)
1. Rituximab: a new therapeutic alternative in rheumatoid arthritis.
Sibilia J; Gottenberg JE; Mariette X
Joint Bone Spine; 2008 Oct; 75(5):526-32. PubMed ID: 18571968
[TBL] [Abstract][Full Text] [Related]
2. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
Shaw T; Quan J; Totoritis MC
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
[No Abstract] [Full Text] [Related]
3. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
4. [Rituximab treatment of rheumatoid arthritis: new evidence].
Nasonov EL
Ter Arkh; 2009; 81(6):82-91. PubMed ID: 19663200
[TBL] [Abstract][Full Text] [Related]
5. Long term treatment of rheumatoid arthritis with rituximab.
Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
[TBL] [Abstract][Full Text] [Related]
6. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
Yukawa N; Mimori T
Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
[TBL] [Abstract][Full Text] [Related]
7. B cell-targeted therapy for rheumatoid arthritis: an update on the evidence.
Looney RJ
Drugs; 2006; 66(5):625-39. PubMed ID: 16620141
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.
Dass S; Vital EM; Emery P
Expert Opin Pharmacother; 2006 Dec; 7(18):2559-70. PubMed ID: 17150009
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for rheumatoid arthritis.
Palylyk-Colwell E; McGahan L
Issues Emerg Health Technol; 2006 Sep; (89):1-4. PubMed ID: 17014062
[TBL] [Abstract][Full Text] [Related]
10. [Anti-CD20 antibody therapy for inflammatory immune diseases].
Tanaka Y
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1801-6. PubMed ID: 17037318
[No Abstract] [Full Text] [Related]
11. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis.
Korhonen R; Moilanen E
Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):13-21. PubMed ID: 19686542
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
Goldblatt F; Isenberg DA
Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S
Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
[TBL] [Abstract][Full Text] [Related]
14. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
Finckh A; Ciurea A; Brulhart L; Möller B; Walker UA; Courvoisier D; Kyburz D; Dudler J; Gabay C;
Ann Rheum Dis; 2010 Feb; 69(2):387-93. PubMed ID: 19416802
[TBL] [Abstract][Full Text] [Related]
15. Rituximab: in rheumatoid arthritis.
Frampton JE; Scott LJ
BioDrugs; 2007; 21(5):333-41: discussion 342. PubMed ID: 17896839
[TBL] [Abstract][Full Text] [Related]
16. New and promising treatments for rheumatoid arthritis.
Looney RJ; Stohl W
Am J Orthop (Belle Mead NJ); 2007 Jul; 36(7 Suppl):18-23. PubMed ID: 17694190
[No Abstract] [Full Text] [Related]
17. Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis.
Jin T; Bokarewa M; Amu S; Tarkowski A
Clin Exp Rheumatol; 2009; 27(3):491-4. PubMed ID: 19604443
[TBL] [Abstract][Full Text] [Related]
18. Current aspects of anti-CD20 therapy in rheumatoid arthritis.
Jacobi AM; Dörner T
Curr Opin Pharmacol; 2010 Jun; 10(3):316-21. PubMed ID: 20189875
[TBL] [Abstract][Full Text] [Related]
19. Rituximab biosimilar CT-P10 for the treatment of rheumatoid arthritis.
Jung JY; Kim JW; Kim HA; Suh CH
Expert Opin Biol Ther; 2019 Oct; 19(10):979-986. PubMed ID: 31498682
[No Abstract] [Full Text] [Related]
20. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.
Rehnberg M; Amu S; Tarkowski A; Bokarewa MI; Brisslert M
Arthritis Res Ther; 2009; 11(4):R123. PubMed ID: 19686595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]